JPRN-UMIN000008487已完成未知
Chiba Refractory Schizophrenia Treatment-LAI study - CREST study
Department of Psychiatry, Graduate School of Medicine, Chiba University0 个研究点目标入组 150 人开始时间: 2012年7月20日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 150
研究概览
简要总结
Of the 43 TRS patients at the 6 months observational period following risperidone long-acting injection initiation, 25 (58%) patients were diagnosed as DSP.Following 6 months of RLAI treatment, 17 of these 25 DSP patients (68%) had responded to RLAI.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who have already received risperidone long- acting injection.
研究者
相似试验
已完成
不适用
Switching From Consta® to Sustenna® in Patients With SchizophreniaSchizophreniaNCT01698216Seoul National University Hospital50
已完成
3 期
Long-Acting Injectable Risperidone in the Treatment of SchizophreniaSchizophreniaSchizoaffective DisorderNCT00132314US Department of Veterans Affairs382
已完成
3 期
Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective DisorderSchizophreniaSchizoaffective DisorderNCT01888107Janssen-Cilag S.p.A.347
已完成
3 期
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic SchizophreniaPsychotic DisorderSchizophreniaNCT00249119Janssen, LP1,579
已完成
不适用
Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality DisorderSchizotypal Personality DisorderNCT00158028Icahn School of Medicine at Mount Sinai25